Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meridian Diagnostics receives all-clear from FDA:

This article was originally published in Clinica

Executive Summary

Meridian Diagnostics has received 510(k)clearance from the FDA for two of its enzyme immunoassays Premier Giardia and Premier Cryptosporidium. The tests can detect the presence of the waterborne parasites Giardia and Cryptosporidium in under two hours from a simple stool specimen, according to the Cincinnati-based company. Giardia, which is transmitted through improperly treated water, infects more than two million people in the US every year and Cryptosporidium is particularly harmful in patients with immuno-compromised conditions such as AIDS. The worldwide market for testing of these parasites is estimated at $20 million annually.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel